Palisade Bio Inc. diskutieren
Palisade Bio Inc.
WKN: A3DZ0T / Symbol: PALI / Name: Palisade Bio / Aktie / Pharmazeutika / Small Cap /
0,34 €
-6,68 %
Sell Seneca Biopharma Inc.
Palisade Bio, Inc. (NASDAQ: PALI) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating.
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. They now have a $1.50 price target on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $22.50 price target on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $22.50 price target on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) had its price target lowered by analysts at Maxim Group from $22.50 to $8.00. They now have a "buy" rating on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $38.00 price target on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Brookline Capital Management. They now have a $16.00 price target on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Wall Street Zen to a "sell" rating.
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $25.00 price target on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $25.00 price target on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Clear Str Llc to a "strong-buy" rating.
Ratings data for PALI provided by MarketBeat
Palisade Bio (PALI) is now covered by Stifel Nicolaus. They set a "buy" rating and a $5.00 price target on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio (PALI) is now covered by HC Wainwright. They set a "buy" rating and a $7.00 price target on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio (PALI) is now covered by Wolfe Research. They set an "outperform" rating and a $7.00 price target on the stock.
Ratings data for PALI provided by MarketBeat
Palisade Bio (PALI) was upgraded by LADENBURG THALM/SH SH to "strong-buy".
Ratings data for PALI provided by MarketBeat
Palisade Bio (PALI) had its "buy" rating reaffirmed by HC Wainwright.
Ratings data for PALI provided by MarketBeat
Palisade Bio (PALI) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $8.00 price target on the stock.
Ratings data for PALI provided by MarketBeat
Neueste Beiträge
Jonestrading in Redwood Trust Inc. diskutieren